Key facts
- Aprovix’s last known valuation is $3.3M (Dec 2016).
- It has raised $880K; the latest was PE Growth/Expansion in Dec 2025.
- Notable investors include Kaikarhenni, Takoa Invest.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Aprovix
- ·The full record, as it builds
Funding rounds
No funding rounds for Aprovix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aprovix
Manufacturer of a diagnostic sampling device intended to contribute to a cervical cancer-free world. The company's device allows women to collect a vaginal fluid sample for lab analysis in the comfort of their own homes, thereby giving them the best prospects of starting early treatment for cancer.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2001
- Employees
- 3
- Website
- aprovix.com/
- Ownership
- Privately Held (backing)
Aprovix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aprovix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aprovix in its N-PORT filings yet. We sweep new filings monthly.